Akebia Therapeutics, Inc.AKBANASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, above historical average.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-40.69M
↑ 56% above average
Average (9y)
$-91.96M
Historical baseline
Range
High:$55.24M
Low:$-264.10M
CAGR
-2.9%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | $-40.69M | -74.0% |
| 2023 | $-23.38M | +68.1% |
| 2022 | $-73.27M | +71.0% |
| 2021 | $-253.02M | -128.6% |
| 2020 | $-110.70M | +58.1% |
| 2019 | $-264.10M | -166.5% |
| 2018 | $-99.10M | -71.5% |
| 2017 | $-57.78M | -204.6% |
| 2016 | $55.24M | +204.6% |
| 2015 | $-52.82M | - |